Clinical trial

Resmetirom in Patients With MASH and HFpEF

NCT07830758

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-09-01

PhasePHASE1

Study timeline

Study start (estimated)2026-09-01Date precision: month

Registry last updated2026-09-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

MASH - Metabolic Dysfunction-Associated Steatohepatitisunresolved

Heart Failure With Preserved Ejection Fraction (HFPEF)unresolved

Interventions

ResmetiromDRUG · verified · RxNorm: resmetirom

PlaceboDRUG

Sponsors & collaborators

Madrigal Pharmaceuticals, Inc.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07830758 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.